STEPHEN VOBACH: Open Payments
NPI 1851377006 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$49,701 in 279 payments from 21 companies in 2025. Trend: 2023 $72,718 · 2024 $40,038 · 2025 $49,701
Speaker / faculty: $43,560Food & beverage: $4,670Travel & lodging: $1,472
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 51 | $25,517 |
| ABBVIE INC. | 46 | $21,040 |
| Otsuka America Pharmaceutical, Inc. | 24 | $469 |
| Neurocrine BioSciences, Inc. | 27 | $459 |
| Axsome Therapeutics, Inc. | 22 | $435 |
| Alkermes, Inc. | 15 | $277 |
| Lundbeck LLC | 16 | $241 |
| Bausch Health US, LLC | 13 | $186 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $165 |
| Corium, LLC | 10 | $160 |
Products named: FANAPT, VRAYLAR, REXULTI, INGREZZA, Auvelity, ARISTADA, CAPLYTA, Azstarys.
Industry payments across TX — which companies pay providers there.
